Immutep (IMM) News Today Add Compare Share Share Headlines Stock AnalysisBuy This Stock All Sources Trusted Sources MarketBeat Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent April 2025 March 2025 February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 Time Period Immutep announces first patient dosed in TACTI-004 Phase III trialMarch 27, 2025 | markets.businessinsider.comHealth Check: Bargain hunters flock to 4D Medical’s discounted raisingMarch 25, 2025 | msn.comImmutep notches upward on first lung cancer patient dosingMarch 25, 2025 | msn.comImmutep announces poster presentation for the TACTI-004 Phase III trialMarch 21, 2025 | markets.businessinsider.comImmutep Ltd (PRRUF) Receives a Buy from Canaccord GenuityMarch 7, 2025 | markets.businessinsider.comWhy Immutep (IMMP) Is Among the Best Australian Stocks to Buy Now?January 27, 2025 | msn.comImmutep announces patient enrollment completed for EFTISARC-NEO Phase II trialJanuary 22, 2025 | markets.businessinsider.comPatient Enrolment Completed for INSIGHT-003January 6, 2025 | finance.yahoo.comImmutep dips as safety test for flagship drug IMP761 shows no adverse effectsDecember 17, 2024 | msn.comImmutep Ltd Reveals Key LAG-3 Binding DiscoveryDecember 16, 2024 | msn.comMolecular insights unlock a targeted approach to cancer immunotherapyDecember 14, 2024 | msn.comASX 300 healthcare stock lifts off on promising new resultsDecember 11, 2024 | msn.comImmutep Ltd Advances Efti in Cancer Treatment TrialsNovember 22, 2024 | markets.businessinsider.comImmutep Limited Passes All AGM ResolutionsNovember 22, 2024 | markets.businessinsider.comImmutep Ltd Sees Increased Stake from Regal FundsNovember 18, 2024 | msn.comAnalysts Offer Insights on Healthcare Companies: Rani Therapeutics Holdings (RANI) and Immutep Ltd (OtherPRRUF)November 18, 2024 | markets.businessinsider.comImmutep price target raised to $7 from $6 at BairdNovember 17, 2024 | markets.businessinsider.comImmutep Reports Promising Phase II Sarcoma Trial ResultsNovember 16, 2024 | markets.businessinsider.comImmutep Reports Promising Phase II Sarcoma Trial ResultsNovember 16, 2024 | markets.businessinsider.comImmutep’s Promising Lung Cancer Trial ResultsNovember 16, 2024 | markets.businessinsider.comImmutep’s Promising Lung Cancer Trial ResultsNovember 16, 2024 | markets.businessinsider.comImmutep Limited: Immutep's Efti Shows Excellent Survival Data from INSIGHT-003 Trial in Non-Small Cell Lung CancerNovember 15, 2024 | finanznachrichten.deImmutep stock jumps 11% on positive data for eftilagimod alphaNovember 15, 2024 | msn.comImmutep announces data from INSIGHT-003 trialNovember 14, 2024 | markets.businessinsider.comImmutep data from Phase II trial presented at CTOSNovember 14, 2024 | markets.businessinsider.comImmutep’s Cancer Trial Shows Promising Survival ResultsNovember 14, 2024 | markets.businessinsider.comImmutep Ltd Reports Promising Results in Sarcoma TrialNovember 14, 2024 | markets.businessinsider.comCanaccord Genuity Sticks to Its Buy Rating for Aroa Biosurgery Ltd (ARX)November 13, 2024 | markets.businessinsider.comCanaccord Genuity Sticks to Its Buy Rating for PYC Therapeutics Limited (PYC)November 13, 2024 | markets.businessinsider.comImmutep reports Q1 cash receipts from custmers $20,000October 29, 2024 | markets.businessinsider.comImmutep Ltd Reports Positive Advances in Cancer TrialsOctober 29, 2024 | markets.businessinsider.comImmutep to Present New Phase IIb Data in PD-L1 Negative (CPS <1) Head and Neck Cancer at ESMO Immuno-Oncology 2024October 28, 2024 | finance.yahoo.comImmutep Faces Cybersecurity Threats: Potential Delays and Liabilities in Product DevelopmentOctober 23, 2024 | markets.businessinsider.comImmutep Limited Announces 2024 AGM DetailsOctober 22, 2024 | markets.businessinsider.comImmutep Limited Announces 2024 Financial PerformanceOctober 22, 2024 | markets.businessinsider.comImmutep Strengthens Transparency with Updated Governance DisclosureOctober 22, 2024 | markets.businessinsider.comImmutep Flat on Test ResultsOctober 17, 2024 | baystreet.caImmutep Announces First-in-Human Phase I Study of IMP761 Progresses to Dose Escalation Portion of TrialOctober 17, 2024 | markets.businessinsider.comImmutep concludes participant enrolment in Phase II breast cancer trialOctober 4, 2024 | msn.comImmutep Completes Patient Enrolment in Randomised Phase II of AIPAC-003 Trial in Metastatic Breast CancerOctober 3, 2024 | markets.businessinsider.comHere's why this beaten-up ASX All Ordinaries stock is surging 48% todaySeptember 24, 2024 | msn.comImmutep snaffles A$3.6M from French government for R&DSeptember 24, 2024 | msn.comBuy Rating Affirmed for Immutep on Promising Efti Outlook Despite Mixed Study InterpretationsSeptember 19, 2024 | markets.businessinsider.comWhy Cettire, Immutep, Paladin Energy, and Westgold shares are sinking todaySeptember 15, 2024 | msn.comAlive and Kicking: Respiri promises breath of life to bottom line after inking US distribution dealSeptember 15, 2024 | msn.comImmutep Ltd Webcast Presentation TranscriptSeptember 14, 2024 | gurufocus.comImmutep Ltd Clinical Results Webinar TranscriptSeptember 14, 2024 | gurufocus.comImmutep Ltd (PRRUF) Receives a Buy from WilsonsSeptember 12, 2024 | markets.businessinsider.comImmutep’s Innovative LAG-3 Focused Therapies Poised to Transform Advanced Cancer Treatments: A Buy Rating OverviewSeptember 11, 2024 | markets.businessinsider.comImmutep Ltd (YP1A.HM)August 29, 2024 | uk.finance.yahoo.com Remove Ads Get Immutep News Delivered to You Automatically Sign up to receive the latest news and ratings for IMM and its competitors with MarketBeat's FREE daily newsletter. Email Address IMM Media Mentions By Week IMM Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. IMM News Sentiment▼0.000.61▲Average Medical News Sentiment IMM News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. IMM Articles This Week▼01▲IMM Articles Average Week Remove Ads Get Immutep News Delivered to You Automatically Sign up to receive the latest news and ratings for IMM and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies GNS News Today ONT News Today BIO News Today PRTC News Today ZBIO News Today OXB News Today FARN News Today FRX News Today APS News Today 4BB News Today Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (ASX:IMM) was last updated on 4/4/2025 by MarketBeat.com Staff From Our PartnersWarning: “DOGE Collapse” imminentElon Strikes Back You may already sense that the tide is turning against Elon Musk and DOGE. Just this week...Altimetry | SponsoredFeds Just Admitted It—They Can Take Your CashThe Government Just Said Your Money Isn't Yours That's right—According to the DOJ, YOUR hard-earned money i...Priority Gold | SponsoredURGENT: Someone's Moving Gold Out of London...People who don’t understand the gold market are about to lose a lot of money. Unfortunately, most so-called “g...Golden Portfolio | SponsoredThree new patents reveal Elon and Trump’s secret “Project America”Right now for a limited time… You can get Tim Bohen’s top 5 Trump stocks for 2025… For only ONE DOLLAR!...Timothy Sykes | SponsoredTrump’s Secret WeaponPlease don't wait—this is your moment to take action. Download your Wealth Protection Guide now, claim your fr...American Alternative | SponsoredTrump Makes Major Crypto AnnouncementTrump Ends the “War on Crypto” I expect it to pump the market, which is why I'm recommending ONE coin to al...Crypto 101 Media | Sponsored“Fed Proof” Your Bank Account with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank ac...Weiss Ratings | SponsoredNow I look stupid. Real stupid... I thought what happened 25 years ago was a once- in-a-lifetime event… but how wrong I was. Because here we...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Immutep Limited Please log in to your account or sign up in order to add this asset to your watchlist. Share Immutep With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy IMM Stock Free IMM Stock Alerts